Table 1. The number of tumors observed in each organ after MNU administration in different dosages.
| 25 mg/kg | 50 mg/kg | 75 mg/kg | ||||
|---|---|---|---|---|---|---|
| p53+/+ | p53+/- | p53+/+ | p53+/- | p53+/+ | p53+/- | |
| Total number of mice | 19 | 26 | 26 | 24 | 20 | 22 |
| Total tumor | 10(52.6%) | 21(80.8%)* | 20(76.9%) | 24(100%)* | 18(90%) | 21(95.5%) |
| TML | 0(0%) | 3(11.5%) | 0(0%) | 13(54.2%)*** | 1(5%) | 13(59.1%)** |
| Adenoma in lung | 8(42.1%) | 9(34.6%) | 17(65.4%) | 7(29.2%)* | 13(65%) | 6(27.2%)* |
| AC in lung | 2(10.5) | 8(30.8%) | 3(11.5%) | 8(33.3%) | 4(20%) | 4(18.2%) |
| TML lung metastasis | 0(0%) | 3(11.5%) | 0(0%) | 7(29.2%)** | 1(5%) | 10(45.5%)** |
| AC in lung + TML lung metastasis | 2(10.5%) | 11(42.3%) | 3(11.5%) | 15(62.5%)*** | 5(25%) | 14(63.7%)* |
| Total lung tumor | 10(52.6%) | 20(76.9%) | 20(76.9%) | 22(91.7%) | 18(90%) | 20(90.9%) |
| TML spleen metastasis | 0(0%) | 2(7.7%) | 0(0%) | 7(29.2%)** | 1(5%) | 6(27.2%) |
| TML liver metastasis | 0(0%) | 2(7.7%) | 0(0%) | 4(16.7%)* | 1(5%) | 7(31.8%)* |
| TML lymph node metastasis | 0(0%) | 2(7.7%) | 0(0%) | 1(4.2%) | 1(5%) | 7(31.8%)* |
| TML kidney Metastasis | 0(0%) | 2(7.7%) | 0(0%) | 6(25%)** | 1(5%) | 6(27.2%)* |
| TML heart metastasis | 0(0%) | 0(0%) | 0(0%) | 2(8.3%) | 0(0%) | 0(0%) |
| Subcutaneous fibrosarcoma | 0(0%) | 1(3.8%) | 0(0%) | 0(0%) | 0(0%) | 3(13.6%) |
*P < 0.05;
**P < 0.01;
***P < 0.001, Significant difference between the FVB-Trp53+/- and Wild-type mice in the same MNU administration group, as assessed using chi-square test. AC, adenocarcinoma in lung; TML, thymic malignant lymphoma.